Tremor
TrialsCompanies

Not investment advice.

Tremor shows what changed in public records. It never tells anyone to buy or sell. Many trial edits are harmless paperwork. Data from ClinicalTrials.gov, the SEC, and the Federal Register.

PrivacyTerms

EXELExelixisRunning, no new patients

Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC

Metastatic Prostate Cancer · Prostate Adenocarcinoma

2Calmworry score, out of 100

No strong warning signs right now. The score counts warning signs; it is not a prediction.

Why this score

  • 3 insiders sold shares within a month

    Since May 26, 2026 · was worth 10, fading over time

    +1.5
Worry score2

Score over time

Stage
Phase 3
Patients
575 (final count)
Started
Oct 19, 2020
Main results expected
Apr 19, 2024
Fully finished
Oct 16, 2026
Results posted
Dec 18, 2025

What counts as success

The trial's main goal(s), called the “primary outcome.”

  • Duration of Progression Free Survival (PFS) Per Response Evaluable Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by Blinded Independent Radiology Committee (BIRC)

    Measured over: Up to a maximum of approximately 30 months (Median duration of follow-up was 14.31 months)

  • Duration of Overall Survival (OS)

    Measured over: Up to a maximum of approximately 45 months (Median duration of follow-up was 24.05 months)

Changes Tremor has spotted

No changes since Tremor started watching this trial.
Show details (technical version)

Score inputs

  • insider_selling_cluster: base 10, now 1.5, since 2026-05-26, fades (half-life)

Raw record changes

  • none yet

Trial ID NCT04446117 · record last updated 2025-12-18 · checked 2026-11-09 15:47 UTC

See the official record on ClinicalTrials.gov (NCT04446117) ↗